BridgeBio Pharma (BBIO) Cash & Equivalents (2017 - 2026)

BridgeBio Pharma has disclosed Cash & Equivalents across 10 years of filings, most recently posting $879.9 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $879.9 million, up 62.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $879.9 million (up 62.76% YoY), and the FY2025 annual result was $570.1 million, down 16.29% from the prior year.
• Cash & Equivalents came in at $879.9 million for Q1 2026 at BridgeBio Pharma, up from $570.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $879.9 million in Q1 2026 to a low of $266.3 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $470.1 million (2022), against an average of $479.2 million.
• Across the five-year window, Cash & Equivalents surged 167.95% in 2022 and plunged 47.28% in 2024, its largest moves.
• BridgeBio Pharma's Cash & Equivalents stood at $376.7 million in 2022, then dropped by 0.2% to $375.9 million in 2023, then jumped by 81.18% to $681.1 million in 2024, then decreased by 16.29% to $570.1 million in 2025, then jumped by 54.33% to $879.9 million in 2026.
• The last three Cash & Equivalents figures came in at $879.9 million (Q1 2026), $570.1 million (Q4 2025), and $283.3 million (Q3 2025), per Business Quant data.